Skip to main content
. 2020 Apr 6;21(7):2545. doi: 10.3390/ijms21072545

Figure 2.

Figure 2

CMV-hDENND1A.V2 transgenic mouse profile. (A) Representative RT-PCR results from ovary and adrenal tissue collected from the three CMV-hDENND1A.V2 founder lines; 7376, 7277, and 7380. (B) Comparison of the relative expression of hDENND1A.V2 mRNA quantified by qRT-PCR in F2 generation ovaries collected from wild-type and CMV-hDENND1A.V2 7376 and 7277 founder transgenic mice, demonstrated elevated ovarian hDENND1A.V2 mRNA expression in Tg1-F2 7376 (**, p= 0.001) and Tg2-F2 7277 (**, p= 0.001), as compared to the wild-type mice. (C) In parallel studies, ovarian Cyp17a1 mRNA levels were also elevated in Tg1-F2 7376 (***, p = 0.0001) and Tg2-F2 7277 (**, p = 0.0001) mice as compared to the wild-type mice (Figure 2C (left)). Adrenal Cyp17a1 mRNA was also increased in Tg2-F2 7277 mice (**, p < 0.001) as compared to the wild-type mice (Figure 2C (middle)). Progesterone levels were augmented in plasma from Tg2-F2 7277 mice (**, p < 0.001) (Figure 2C (right)). WT, wild-type; Tg, transgenic; F2, second generation.